Project Grant R01CA285792
Award Date
9/19/24
Completion Date
8/31/29
Dollars Obligated
$692K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
This $571,271 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) aims to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in vivo targeting...
This federal Project Grant award of $568,151 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a real-time functional photoacoustic imaging platform to enable sensitive detection of prostate cancer tumors and accurate characterization of their aggressiveness. The key products and services to be delivered through this 5-year award include: Optimization of biocompatible polyacrylamide hydrogel nanoparticle (PAA NP) probes for...
This $472,458 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Texas Southwestern Medical Center to examine the role of the PTPN1 protein in the development of therapy- and castration-resistant prostate cancer. The key objectives are to: 1) investigate how anti-androgen therapies regulate PTPN1 gene expression and its impact on the transdifferentiation of prostate cancer cells, 2) identify the downstream...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...
The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University from February 1, 2025 to January 31, 2030. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy (PSMA-RPT) on glutaminolysis, a key metabolic pathway, in experimental models of prostate cancer (PC) and renal cell carcinoma (RCC). The research will assess...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This $400,000 Project Grant awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel, RNA-interference-based therapeutic to treat prostate cancer. The funding recipient, Nuago Therapeutics Inc., is leveraging research conducted at Northwestern University to develop a therapeutic using short interfering RNA (sRNA) molecules that target genes essential for cancer cell survival. The project aims to evaluate the uptake and...
The National Cancer Institute (NCI) awarded a $602,361 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Yale University to develop deep learning-based models for personalized treatment planning of prostate cancer patients receiving 177Lu-PSMA radiopharmaceutical therapy (RPT). The project aims to leverage PSMA-PET and 177Lu-PSMA SPECT imaging data collected during RPT to build predictive dosimetry models that can enable personalized dose calculations and optimize...